^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + magrolimab (ONO-7913) (CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Excerpt:
...- Patients with newly diagnosed AML with poor risk karyotype or complex karyotype per ELN2017 and/or TP53 deletions/mutations of any age >/= 18 years of age will be eligible for the Phase II (frontline cohort) regardless of eligibility or fitness for intensive chemotherapy...
Trial ID:
Source:
Title:
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Published date:
11/04/2021
Excerpt:
7 of 8 ND pts with TP53m were evaluable (1 still in cycle 1) with a CR/CRi in 100% (7/7), CR in 86% pts (6/7)... The combination of AZA VEN Magro was safe. High CR/CRi (94%) rates and CR rates (81%) were noted in ND pts, with majority (82%) ELN adverse risk.
Secondary therapy:
azacitidine
DOI:
10.1182/blood-2021-153638
Trial ID:
